GNFT Genfit SA

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 7, 2025 French legal announcements bulletin n°55 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on June 17, 2025, at 10:00 am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

All documentation regarding this Shareholders’ Meeting will be available to shareholders in accordance with existing regulations, and will be available on the Company’s website, in the Financials section under the Shareholders Meeting tab (.

The General Meeting will be broadcasted live and will be available on the Company's website in the same section. A recording of the General Meeting will be available on the Company's website within the time frame specified by regulations.

For this 2025 Combined General Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform. A tutorial to familiarize shareholders with this online voting platform will be made available in the same section of the website as soon as the platform is opened.

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. 

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website () and the AMF's website (), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: |

PRESS RELATIONS | Media

Stephanie Boyer – Press relations | Tel: |

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | |        


1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®.

Attachment



EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genfit SA

 PRESS RELEASE

GENFIT Reports First Quarter 2025 Financial Information

GENFIT Reports First Quarter 2025 Financial Information Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025.1 Cash position As of March 31, 2025, the Company’s cash and cash equivalents amounted to €129.5 million compared with €74.0 million as of March 31, 2024, and €81.8 million a...

 PRESS RELEASE

GENFIT : Information financière du premier trimestre 2025

GENFIT : Information financière du premier trimestre 2025 Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 22 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui sa position de trésorerie au 31 mars 2025 et son chiffre d’affaires pour les trois premiers mois de 2025.1 Situation de Trésorerie  Au 31 mars 2025, la trésorerie et les équivalents de trésorerie de la Société s’élevaie...

 PRESS RELEASE

GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la s...

GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), le 20 mai, 2025 – GENFIT (Nasdaq et Euronext : GNFT), société́ biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui qu’Iqirvo® d'Ipsen1 a obtenu l’approbation du prix et du remboursement en Italie pour le traitement de la cholangite biliaire ...

 PRESS RELEASE

GENFIT to receive a €26.5 million milestone payment following the appr...

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen’s Iqirvo®1 has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC). This major step unlocks a new milestone payment of €26.5 million under our Licensing...

 PRESS RELEASE

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fi...

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024). Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to the growing interest of institutional and individual shareholders,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch